The content on this site is intended for healthcare professionals only
Dr Gil Morgan from OncoAlert gives his oncology highlights from social media for the week of August 4th - 10th, 2023.
He begins by highlighting the FDA approval of LONSURF (trifluridine/tipiracil) with bevacizumab for previously treated metastatic colorectal cancer following prior approval of single-agent LONSURF.
Dr Morgan also covers results from the KEYNOTE 671 trial of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early-stage non-small cell lung cancer.
He concludes by inviting colleagues to the 'Multidisciplinary Perspectives in Breast Cancer' conference taking place on October 6th.
Follow Dr Morgan on twitter: @OncoAlert
Follow ecancer on twitter: @ecancer
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
The Southeast Asian Breast Cancer Symposium; background, aims and successes
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC
Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours
VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
